BPM
ACOR

Bowling Portfolio Management’s Acorda Therapeutics ACOR Stock Holding History

Bowling Portfolio Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-702
Closed -$1.12M – 418
2019
Q1 		$1.12M Sell
702
-2
-0.3% -$3.6K 0.18% 203
2018
Q4 		$1.32M Buy
704
+591
+523% +$1.29M 0.23% 143
2018
Q3 		$267K Buy
+113
New +$350K 0.04% 316
2017
Q3 		– Sell
-341
Closed -$807K – 427
2017
Q2 		$807K Buy
+341
New +$676K 0.12% 240

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bowling Portfolio Management's ACOR Position: Q2 2019 in Review

Bowling Portfolio Management sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 702 shares — an estimated $1.12M sold.

Bowling Portfolio Management first reported a position in ACOR in Q2 2017 and held it in 4 quarters. The position peaked at $1.32M in Q4 2018. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

  • Bowling Portfolio Management reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Bowling Portfolio Management sold 702 Acorda Therapeutics shares in Q2 2019, an estimated $1.12M.
  • Bowling Portfolio Management first reported a position in Acorda Therapeutics in Q2 2017 and held it in 4 quarters.
  • Bowling Portfolio Management's Acorda Therapeutics position peaked at $1.32M in Q4 2018.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on Bowling Portfolio Management's 13F filing for Q2 2019, filed 25 Jul 2019.